GLP-1 Drug Interactions: What Happens When Ozempic, Mounjaro, and Others Meet Your Other Medications | Research

The takeaway

Most GLP-1 drug interactions are clinically insignificant, but tirzepatide can affect oral contraceptive levels and oral semaglutide can alter thyroid medication absorption — requiring monitoring.

2-minute half-life
Native GLP-1 lasts just 2 minutes in the body — the engineering that extends this to days or weeks (fatty acids, albumin binding, Fc fusion) varies dramatically between approved drugs

What the researchers found

This comprehensive review maps the pharmacokinetics and drug interactions of all approved GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide) plus tirzepatide (the dual GLP-1/GIP agonist). Native GLP-1 has a half-life of just 2 minutes — the structural modifications that extend this (amino acid substitutions, fatty acid conjugation, albumin binding, Fc fusion) vary by drug and produce dramatically different pharmacokinetic profiles.

The review finds that most drug-drug interactions (DDIs) with GLP-1 RAs are clinically insignificant — they don't interfere with liver enzymes or drug transporters. The main DDI mechanism is delayed gastric emptying, which slows absorption of co-administered oral drugs. However, two notable exceptions require monitoring: tirzepatide significantly altered oral contraceptive exposure, and oral semaglutide affected levothyroxine levels. Additionally, GLP-1 drug-induced changes in body fat, kidney filtration, and liver enzyme activity could affect other drugs in ways not yet well understood.

Why it matters

Millions of people now take GLP-1 drugs alongside other medications. Understanding drug interactions is critical for patient safety — especially for oral contraceptives (failure could mean unintended pregnancy) and thyroid medication (under-dosing could cause hypothyroid symptoms). This review provides the most comprehensive pharmacokinetic comparison of all approved GLP-1/GIP drugs in one place, making it an essential reference for prescribers managing patients on multiple medications.

The numbers in context

5 drugs reviewed · native GLP-1 half-life: 2 min · DDI concerns: oral contraceptives (tirzepatide) + levothyroxine (oral semaglutide) · 30 PK models developed · delayed gastric emptying = main DDI mechanism

How the study worked

Comprehensive narrative review synthesizing pharmacokinetic data, drug interaction studies, and pharmacokinetic modeling approaches for all approved GLP-1 RAs and tirzepatide. Covers structural modifications, metabolism, renal excretion, and both enzyme/transporter-mediated and mechanism-of-action-mediated drug interactions.

Who was studied

Not applicable (review of pharmacokinetic and drug interaction data across multiple clinical studies)

What this study cannot tell us

As a narrative review, it synthesizes existing data rather than generating new findings. Many potential DDIs (especially those mediated by body composition changes or altered CYP activity) remain poorly studied. The review focuses on approved drugs and may not cover investigational GLP-1 compounds. Individual patient variability in pharmacokinetics is acknowledged but not modeled. Post-marketing DDI data may be limited for newer drugs like tirzepatide.

How to read the evidence

This is a comprehensive pharmacokinetic review published in a drug development journal, synthesizing clinical data across all approved GLP-1/GIP drugs. The 'Strong' grade reflects the thoroughness, clinical relevance, and the quality of the underlying pharmacokinetic data reviewed.

When this study was published

Published in 2025, this is the most current comprehensive comparison of GLP-1 drug pharmacokinetics and interactions, including tirzepatide data that wasn't available in earlier reviews.

The bigger picture

As GLP-1 drugs move from diabetes specialty prescribing to widespread primary care and weight management use, understanding their drug interactions becomes essential. The average patient taking a GLP-1 drug is on multiple other medications — diabetes drugs, blood pressure meds, cholesterol pills, thyroid supplements, and contraceptives. This review is a clinical reference for ensuring these combinations are safe.

Questions still open

Does GLP-1-mediated weight loss change the effective dose of other medications through altered volume of distribution?
How does the delayed gastric emptying DDI mechanism change with long-term GLP-1 use as tolerance may develop?
Should oral contraceptive users switch to non-oral methods when starting tirzepatide?

Common questions

Can I take my other medications at the same time as my GLP-1 drug?

For injectable GLP-1 drugs (semaglutide injection, dulaglutide, tirzepatide), timing of other oral medications is generally not critical. For oral semaglutide (Rybelsus), the specific dosing instructions (take on an empty stomach with a sip of water, wait 30 minutes before other food or pills) are designed to ensure absorption of the semaglutide itself. The main concern is that GLP-1 drugs slow stomach emptying, which can delay absorption of other pills — but this is usually clinically insignificant.

Why would tirzepatide affect birth control pills?

Tirzepatide slows gastric emptying, which means oral contraceptives spend more time in the stomach before reaching the intestine where they're absorbed. This altered absorption pattern can reduce the blood levels of contraceptive hormones. The effect was significant enough in studies that women on tirzepatide may need to consider backup contraception or switch to non-oral methods (patches, IUDs, injections) to maintain protection.

Read the original research

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Drug design, development and therapy, 19, 3509-3537

View on PubMed ↗Publisher’s paper ↗

Citation

Min, Jee Sun; Jo, Seong Jun; Lee, Sangyoung; Kim, Duk Yeon; Kim, Da Hyun; Lee, Chae Bin; Bae, Soo Kyung. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy, 19, 3509-3537. https://doi.org/10.2147/DDDT.S506957